Last reviewed · How we verify
NCT06773195
A Phase 1/2 Study of Combined JAK/ERK Inhibition in Patients With Myelofibrosis
Phase 1/Phase 2 trial testing Ulixertinib in Myelofibrosis in 37 participants. Currently enrolling.
1 January 2028
Quick facts
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 37 |
| Start date | 7 January 2025 |
| Primary completion | 1 January 2028 |
| Estimated completion | 1 January 2028 |
| Sites | 9 locations across United States |
Drugs / interventions tested
- Ulixertinib (ulixertinib) — full drug profile →
- Ruxolitinib (RUXOLITINIB) — full drug profile →
Conditions studied
- Myelofibrosis — all drugs for Myelofibrosis →
Sponsor
Memorial Sloan Kettering Cancer Center — full company profile →
Who can join
18 and older, any sex, with Myelofibrosis. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Dose Limiting Toxicity evaluable participants
Time frame: up to 28 days
If none of the initial 3 patients in a cohort experience a dose limiting toxicity (DLT), then the next dose level will be studied in another cohort of 3 patients. If 1 of the initial 3 patients at a given dose level experience a DLT, up to 3 additional patients will be treated at that same dose level. Escalation will continue if not more than 1 of the 6 patients experience a DLT. -
Response to therapy
Time frame: at week 25
as defined by International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT working criteria)
Sponsor's own description
The researchers are doing this study to find out whether the combination of ruxolitinib and ulixertinib is a safe and effective treatment for people with myelofibrosis. The researchers will test different doses of ulixertinib to find the highest dose that causes few or mild side effects in participants when given in combination with ruxolitinib.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Molecular Frameworks for ERK1/2 Inhibition: Lessons from Synthetic and SAR Explorations.
Muthukumar V, Vashishth A, Maniam S, Ghosh B. · · 2025 · PMID 41487177 · DOI 10.1021/acsomega.5c10213
Verify or expand the search:
- PubMed search for NCT06773195
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ulixertinib
Trials testing the same drug.
- NCT05985954 — Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in P · Phase 1 · recruiting
- NCT05804227 — Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas · EARLY_PHASE1 · recruiting
- NCT05221320 — Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies · Phase 2 · terminated
- NCT04488003 — Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations · Phase 2 · terminated
- NCT04145297 — Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas · Phase 1 · completed
Other recruiting trials for Myelofibrosis
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06781099 — Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis · NA · recruiting
- NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting
- NCT07342712 — Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation Levels · active not recruiting
- NCT06533813 — Clinical Epidemiology in Contemporary Patients With Myelofibrosis. · recruiting
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
- NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06773195 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06773195.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing